Detalhe da pesquisa
1.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858723
2.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120223
3.
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Oncologist
; 22(1): 25-32, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789775
4.
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Oncologist
; 26(8): e1483, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33978307
5.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
J Clin Oncol
; 42(17): 2050-2060, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513188
6.
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
J Am Coll Surg
; 237(2): 247-256, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37194964
7.
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Int J Radiat Oncol Biol Phys
; 113(1): 117-124, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34990776
8.
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).
NPJ Breast Cancer
; 8(1): 127, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36450763
9.
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
NPJ Breast Cancer
; 8(1): 18, 2022 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173164
10.
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Cancer Discov
; 11(10): 2474-2487, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941592
11.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
J Clin Oncol
; 39(21): 2375-2385, 2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077270
12.
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
J Clin Oncol
; 38(36): 4274-4282, 2020 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119476